Ablynx reports further data on RA antibody

Monday 25 June 2012

Ablynx NV said that fresh data from a trial of its anti-tumour necrosis factor-alpha antibody for rheumatoid arthritis, ozoralizumab (ATN-103), has shown some promising results, at least one of which was unexpected.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium